Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated November 17, 2025, discloses insider trading activity in compliance with Article 19 of Regulation No. 596/2014 on market abuse. The company is a leading global healthcare firm headquartered in Denmark, employing approximately 78,400 people across 80 countries and marketing products in around 170 countries.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Purchase of Shares |
| Instrument | Novo Nordisk B Shares (DK0062498333) |
| Volume | 6,450 shares |
| Price per Share | DKK 312.50 |
| Total Transaction Value | DKK 2,015,625.00 |
| Transaction Date | November 17, 2025 |
| Exchange | Nasdaq Copenhagen |
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely reports an initial notification of a share purchase by a board member.
Guidance, Outlook, and Risks
The document contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific insider transaction by Stephan Engels, a Member of the Board of Directors.
Key Facts for Investor Verification
- Stephan Engels, a Member of the Board of Directors, purchased 6,450 Novo Nordisk B shares.
- The transaction occurred on November 17, 2025, on the Nasdaq Copenhagen exchange.
- The average price paid was DKK 312.50 per share, totaling DKK 2,015,625.00.
- This filing is a regulatory disclosure of insider trading and does not contain quarterly or annual financial results.